The Foster City, California-based biotech said today that its IMerge trial of imetelstat – vying to become the first telomerase inhibitor to reach the market – hit its objectives in patients ...

"In order for cancer cells to proliferate indefinitely, they need to activate telomerase to lengthen short telomeres." Thus, altering CST protein activity with drugs could inhibit cancer cell ...

In another milestone, Rytelo has also become the first drug in the telomerase inhibitor class to be approved anywhere in the world. Telomerase has been on the radar of the pharma industry for ...

You have full access to this article via your institution. So, can transformation really occur in the absence of telomerase activity or an alternative telomere-maintenance strategy? Telomerase ...

The first model has a targeted disruption in the gene that encodes the essential RNA component of telomerase, mTerc. These mice have generalized stem cell proliferative defects of the ...